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Abstract 
BACKGROUND: Cutaneous angiosarcoma of the head and neck region is a subtype of cutaneous angiosarcoma 
with an unfavourable prognosis. Diagnosis is often delayed. 
PATENTS AND METHODS: The setting is an Academic Teaching Hospital Skin Cancer Center. Eight Caucasian 
patients could be identified, 5 men and 3 women. Delay to diagnosis was between 12 to 4 months (mean 7.8 ± 
2.9 months). The diagnosis was confirmed in all cases by histopathology and immunohistochemistry. 
Hematoxylin-eosin, Giemsa, PAS, iron and reticulin stains were performed. Endothelial markers such as CD31, 
CD34, and Ki67 for proliferation assessment were used in all tumours. Other markers used included pan-
cytokeratin (CK), CK7, CK20, ERG, CD 40 and c-MYC. Tumours were classified as localised versus multifocal or 
diffuse form. Tumour staging was performed according to the 8th edition of the AJCC. The mean age of patients 
was 79 years ± 26.4 years. The male to female ratio was 1.7. Tumour classification was diffuse in 2 patients, 
multilocular in one and localised in 5 patients. In 5 of 8 patients, a multimodal treatment was performed, one had 
radiotherapy alone, in another patient surgery was performed, and radiotherapy is planned. The mean OS was 
26.4 months ± 24.5 months. 
CONCLUSION: Cutaneous angiosarcoma of the head and neck is an aggressive tumour with a poor prognosis. 
Although surgery remains a cornerstone of treatment, the tumour size at first presentation may be too large, and 
the elderly patients maybe not suitable for extensive surgery. Therefore, multimodal treatment with adjuvant 
radiotherapy and/ or chemotherapy is necessary. Multimodal treatment offers a better outcome than radiotherapy 
or chemotherapy alone. Stealth liposomal encapsulated doxorubicin is a therapeutic option for elderly patients 
with improved safety compared to conventional doxorubicin. 
 
 
 
 
 
 
Introduction 
 
Cutaneous angiosarcoma of the head and 
neck is a rare tumour entity of vascular origin. It 
comprises about half of all angiosarcomas and 
accounts for 1% of all soft tissue sarcomas. This 
tumour is notorious for its aggressive and relentless 
progression with frequent local recurrence and distant 
metastasis. It affects mainly older people with a mean 
age of 73 years. Due to its scarcity and innocuous 
appearance at an early stage diagnosis is often 
delayed for months. Bleeding is one of the leading 
symptoms that is responsible for the first consultation. 
However, bleeding is not an early sign [1].  
A study of the National Cancer Institute's 
Surveillance, Epidemiology, and End Results Program 
recorded 434 cases of cutaneous angiosarcoma from 
1973 to 2007 with a comparable incidence in men and 
women. Caucasians represented the majority of 
patients compared to patients with Asian or African 
descent. Survival rates are dependent on age, 
anatomical site, and stage of the disease. In this 
study, patients < 50 years had a 10-year relative 
survival rate of 71.7%, whereas patients ≥ 50 years 
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had a 36.8% 10-year survival rate. Tumours of the 
scalp and neck had a poor survival rate (13.8% 10-
year relative survival rate) compared to tumours on 
the trunk (75.3% 10-year survival rate). Tumours 
localised to the skin had a better prognosis (53.6% 
10-year relative survival rate) than those with the 
regional or distant stage (19.0% and 6.2%) [2].  
Scalp sarcoma tends to be larger at the time 
of diagnosis. That is responsible for a poorer 
prognosis than facial angiosarcoma. An analysis on 
50 patients with cutaneous head and neck 
angiosarcomas from the Princess Margaret Cancer 
Centre, Toronto / Ontario, Canada, estimated a 5-year 
overall survival (OS) rate of 9% for scalp tumours and 
26% for tumours of the face. In multivariate Cox 
proportional hazards analysis of their data, scalp 
location was independently prognostic for mortality 
(hazard ratio [HR], 2.10; 95% CI, 1.03-4.28; p = .04) 
[3]. 
 
 
Patients and Methods 
 
Patients were seen and treated at the 
Department of Dermatology and Allergology, Skin 
Cancer Center. Delay to diagnosis was between 12 to 
4 months (mean 7.8 ± 2.9 months). Differential 
diagnoses were lentigo, bruising, rosacea, squamous 
cell carcinoma and erysipelas.  
The diagnosis was confirmed in all cases by 
histopathology and immunohistochemistry. 
Hematoxylin-eosin, Giemsa, PAS, iron and reticulin 
stains were performed. Endothelial markers such as 
CD31, CD34, and Ki67 for proliferation assessment 
were used in all tumours. Other markers used 
included pan-cytokeratin (CK), CK7, CK20, ERG, CD 
40 and c-MYC. 
Tumours were classified as localised versus 
multifocal or diffuse form. Tumour staging was 
performed according to the 8
th
 edition of the AJCC [4]. 
The demographics are listed in Table 1. 
Table 1: Demographics of head and neck cutaneous 
angiosarcoma 
 Age Sex Localization Size (cm) Remarks TNM 
1 79 yrs F Scalp, temporoparietal 20 ulcerations, bleeding pT4N0M0 
2 74 yrs M Cheek 3.5 relapse after 6 yrs. pT1N0M0 
3 81 yrs F Scalp 30 ulceration, bleeding pT4N1M0 
4 85 yrs M Scalp 20 ulceration, bleeding pT4N1M0 
5 66 yrs M Cheek 4 Oedema pT2N0M0 
6 82 yrs F Scalp 2 multilocular, bleeding pT2N0M0 
7 66 yrs M Nose 6 oedema, redness pT2N0M0 
8 79 yrs M Scalp 12 Bleeding pT3N0M0 
 
The mean age was 79 years ± 26.4 years. 
The male to female ratio was 1.7. Tumour 
classification was diffuse in 2 patients, multilocular in 
one and localised in 5 patients (Figure 1).  
 
Figure 1: Cutaneous angiosarcoma of the head and neck region; A) 
Localized patch; B) Localized nodule; C) Multifocal tumour; D) 
Diffuse tumour 
 
In 5 of 8 patients, a multimodal treatment was 
performed, one had radiotherapy alone, in another 
patient surgery was performed, and radiotherapy is 
planned (Figure 2). The mean OS was 26.4 months ± 
24.5 months (Table 2). 
 
Figure 2: Cutaneous angiosarcoma, patient #8; A) Primary 
presentation – “bruising after local trauma”; B) Large localized scalp 
tumor after shaving; C) After surgery with curative intent (safety 
margin 2 cm), stable meshed graft transplant; D) and E) 
Histopathology and immunohistochemistry of the tumour; D) 
Irregular vascular proliferations interposed by the dermal collagen 
fibers. Endothelial cells with atypical nuclei, prominent toward the 
lumen, mitotic figures (Hematoxylin-eosin x 4); E) 
Immunoperoxidase staining for CD31, strongly expressed by the 
endothelial tumour cells (x 20); F) Immunoperoxidase staining with 
Ki67 demonstration a highly proliferative fraction of almost 100 % of 
tumour cells (x 20) 
 
 
Discussion 
 
The mainstay of treatment of cutaneous 
angiosarcoma of the head and neck is surgery. 
Surgery with curative intent as the initial treatment is 
significantly associated with improved overall survival 
[5].  
However, complete excision is not always 
possible. In such a situation, multimodal regimens 
seem to improve the outcome [6]. A trial from the 
Mayo Clinic analysed 55 patients with angiosarcoma 
localised to the face or scalp. Multimodal treatment 
received 73% of patients (the combination of surgery, 
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radiation therapy, and/or chemotherapy), 15% were 
treated only surgically, 95 with chemotherapy, 2% with 
radiation alone and 2% had observation alone. The 5-
year OS was 38%. On univariate analysis, the use of 
multimodality therapy (vs no multimodality therapy) 
was associated with higher 5-year OS (46% [26% vs 
16%) [7].  
Table 2: Treatment of head and neck cutaneous angiosarcoma 
and outcome 
 Treatment Safety Overall Survival 
1 
Liposomal doxorubicin (20 mg/m
2
) 
followed by electron beam (total 40 Gy) 
Palmoplantar dysesthesia (CTC 0) 
radiation-induced erythema (CTC 2) 
40 months 
2 
Surgery followed by electron beam (total 
40 Gy) 
Radiation-induced erythema (CTC 2) 80 months 
3 
Liposomal doxorubicin (20 mg/m
2
) 
followed by electron beam (total 40 Gy) 
Anemia & lymphopenia (CTC 2); 
radiation-induced erythema (CTC 2) 
9 months 
4 Electron beam (total 40 Gy) Radiation-induced erythema (CTC 2) 3 months 
5 
Paclitaxel followed by electron beam 
(total 40 Gy) 
Radiation-induced erythema (CTC 3) 6 months 
6 Electron beam (total 40 Gy) Radiation-induced erythema (CTC 2) 44 months 
7 
Surgery followed by electron beam (total 
40 Gy) 
Post-radiation-erythema (CTC 3) 80 months 
8 Surgery, radiation is planned - > 4 months 
 
Radiotherapy is most often used in 
combination with surgery. A meta-analysis from South 
Korea demonstrated that OS of the radiation therapy 
and chemotherapy group (37.0 ± 0.0 months) was 
significantly longer than that of the radiation therapy 
group alone (22.7  ±  7.6 months) or the chemotherapy 
group alone (15.1  ±  4.6 months) [8]. This is in one line 
with a trial from Osaka, Japan, that demonstrated 
patients treated with both surgery and radiotherapy (2-
year OS: 45.8%) had a significantly better OS than 
patients treated with either surgery or radiotherapy 
alone (2-year OS: 11.1%) and patients treated with 
neither surgery nor radiotherapy (2-year OS: 0%) [9]. 
Considering chemotherapy in elderly patients, 
taxanes showed a response rate of 83.3% and a 
median progression-free survival of seven months, 
compared to non-liposomal doxorubicin with a 
response rate of 50% and median progression-free 
survival of 3months [10]. Taxanes show anti-
angiogenic activity. The conventional doxorubicin 
therapy bears a high risk of cardiotoxicity, that leads 
to the cessation of the treatments. This has not been 
observed with stealth liposomal doxorubicin [11]. 
In our series, advanced tumour stages and 
age > 70 years was characteristic. Initial differential 
diagnoses were bruising, lentigo-like hyperpigmen-
tation and rosacea. Most patients presented to the 
doctor because of bleeding. None of the tumours was 
diagnosed at outpatient cancer screenings. 
In conclusion, cutaneous angiosarcoma of the 
head and neck is a rare but aggressive vascular 
malignancy with a less favourable prognosis than the 
counterparts on trunk or extremities. Many patients 
are older than 70 years of age that needs to be 
considered for multimodal treatment. Surgery plus 
radiotherapy is the treatment of choice. When 
chemotherapy is necessary, stealth liposomal 
doxorubicin offers a better safety profile for this age 
group that conventional doxorubicin or taxanes [11], 
[12], [13]. 
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